Union Bancaire Privee UBP SA Grows Stock Holdings in Gilead Sciences, Inc. $GILD

Union Bancaire Privee UBP SA grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 93.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,129 shares of the biopharmaceutical company’s stock after acquiring an additional 6,810 shares during the period. Union Bancaire Privee UBP SA’s holdings in Gilead Sciences were worth $1,734,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of GILD. Trivium Point Advisory LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares during the period. Binnacle Investments Inc increased its holdings in Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 83 shares during the period. Hemington Wealth Management raised its position in Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares in the last quarter. Ignite Planners LLC raised its position in Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares in the last quarter. Finally, Archer Investment Corp lifted its holdings in shares of Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after buying an additional 87 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the chief financial officer owned 179,191 shares in the company, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 309,280 shares of company stock valued at $44,068,850 in the last ninety days. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on GILD shares. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Barclays began coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price objective for the company. UBS Group increased their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Rothschild & Co Redburn boosted their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Price Performance

GILD opened at $137.21 on Friday. The firm has a market capitalization of $170.34 billion, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.85 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The business’s 50-day moving average is $142.69 and its two-hundred day moving average is $127.77. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the prior year, the firm posted $1.90 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.